368 related articles for article (PubMed ID: 30451326)
1. Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature.
Sellah D; Saint-Jean M; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e159-e161. PubMed ID: 30451326
[No Abstract] [Full Text] [Related]
2. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
Jang S; Venna S
J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
[No Abstract] [Full Text] [Related]
3. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
Eglmeier J; Debus D; Schultz ES
Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
[No Abstract] [Full Text] [Related]
4. Brentuximab induced CD30
Nikolaou V; Iliakis T; Marinos L; Economidi A; Panayiotidis P; Rigopoulos D; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e147-e148. PubMed ID: 30520137
[No Abstract] [Full Text] [Related]
5. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
6. Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
Saiag P; Blom A
Lancet; 2023 Sep; 402(10404):751-753. PubMed ID: 37451294
[No Abstract] [Full Text] [Related]
7. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
Topalian SL; Bhatia S; Amin A; Kudchadkar RR; Sharfman WH; Lebbé C; Delord JP; Dunn LA; Shinohara MM; Kulikauskas R; Chung CH; Martens UM; Ferris RL; Stein JE; Engle EL; Devriese LA; Lao CD; Gu J; Li B; Chen T; Barrows A; Horvath A; Taube JM; Nghiem P
J Clin Oncol; 2020 Aug; 38(22):2476-2487. PubMed ID: 32324435
[TBL] [Abstract][Full Text] [Related]
8. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B
Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007
[No Abstract] [Full Text] [Related]
9. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
10. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.
Haug V; Behle V; Benoit S; Kneitz H; Schilling B; Goebeler M; Gesierich A
Br J Dermatol; 2018 Oct; 179(4):993-994. PubMed ID: 29758087
[No Abstract] [Full Text] [Related]
11. Non-Melanoma Skin Cancers: Biological and Clinical Features.
Cives M; Mannavola F; Lospalluti L; Sergi MC; Cazzato G; Filoni E; Cavallo F; Giudice G; Stucci LS; Porta C; Tucci M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751327
[TBL] [Abstract][Full Text] [Related]
12. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
[No Abstract] [Full Text] [Related]
13. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
Tran DC; Colevas AD; Chang AL
JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
[No Abstract] [Full Text] [Related]
14. Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients.
Winkler JK; Dimitrakopoulou-Strauss A; Sachpekidis C; Enk A; Hassel JC
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e389-e391. PubMed ID: 28256019
[No Abstract] [Full Text] [Related]
15. Preserved Renal Allograft Function and Successful Treatment of Metastatic Merkel Cell Cancer Post Nivolumab Therapy.
Singh P; Visger Von J; Prosek J; Rovin B; Pesavento TE; Olencki T; Pandey D
Transplantation; 2019 Feb; 103(2):e52-e53. PubMed ID: 30365468
[No Abstract] [Full Text] [Related]
16. Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?
Dasanu CA; Del Rosario M; Codreanu I; Hyams DM; Plaxe SC
J Oncol Pharm Pract; 2019 Jan; 25(1):214-216. PubMed ID: 29933728
[TBL] [Abstract][Full Text] [Related]
17. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
18. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.
Oliveira LJC; Gongora ABL; Barbosa FG; Dos Anjos CH; Munhoz RR
J Immunother Cancer; 2018 Nov; 6(1):130. PubMed ID: 30482243
[TBL] [Abstract][Full Text] [Related]
19. Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma.
Saiag P; Blom A
Lancet; 2022 Sep; 400(10357):976-977. PubMed ID: 36108656
[No Abstract] [Full Text] [Related]
20. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]